ArticleNature communications2026
Genotype epigenome phenotype integration reveals peripheral immune contributions to type I bipolar disorder.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genotype epigenome phenotype integration reveals peripheral immune contributions to type I bipolar disorder.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Immune dysfunction has been increasingly implicated in bipolar disorder, but the underlying mechanisms remain unclear. To address this, we profile 833 genome-wide chromatin immunoprecipitation sequencing datasets spanning five histone marks in peripheral blood immune cells from 88 Type I bipolar disorder patients and 92 controls, integrating them with whole-genome sequencing and clinical data. We identify disease-associated cis-regulatory elements and genetically influenced regulatory elements, revealing immune signatures and pathways involving calcium signaling and endoplasmic reticulum transport. By integrating genetic risk variants, differential and genetically influenced regulatory elements, and regulatory element-gene links, we prioritize 39 driver genes, 28 of which are exclusively supported by blood evidence. We further stratify patients into five epigenomic subtypes with distinct clinical features and genetic risk profiles and identify compounds that reverse disease-associated epigenomic signatures. Here, we combine immune epigenomics with genetics and clinical traits to identify driver genes, patient subtypes, and therapeutic candidates, highlighting immune contributions to type I bipolar disorder pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.